In Vitro Pharmacodynamics of Polymyxin B and Tigecycline Alone and in Combination against Carbapenem-Resistant Acinetobacter baumannii

被引:61
作者
Hagihara, Mao [1 ,2 ]
Housman, Seth T. [1 ]
Nicolau, David P. [1 ]
Kuti, Joseph L. [1 ]
机构
[1] Hartford Hosp, Ctr Anti Infect Res & Dev, Hartford, CT 06115 USA
[2] Aichi Med Univ, Nagakute, Aichi, Japan
关键词
CRITICALLY-ILL PATIENTS; TIME-KILL; POPULATION PHARMACOKINETICS; ANTIMICROBIAL AGENTS; MULTIDRUG-RESISTANCE; PNEUMONIA MODEL; UNITED-STATES; COLISTIN; INFECTIONS; MANAGEMENT;
D O I
10.1128/AAC.01624-13
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Carbapenem-resistant Acinetobacter baumannii is increasing in prevalence. Polymyxin B and tigecycline are among the most active antibiotics used against this pathogen in vitro. Past in vitro studies, however, neglected the importance of simulating exposures observed in humans to determine their antibacterial effects. In this study, four carbapenem-resistant A. baumannii isolates were evaluated using an in vitro pharmacodynamic model. Free-drug exposures using 1 mg/kg of body weight of polymyxin B every 12 h (q12h), 100 and 200 mg tigecycline q12h, and the combination of these regimens were simulated. The microbiological responses to these treatments were measured by the change in log(10) CFU/ml over 24 h and the area under the bacterial killing and regrowth curve (AUBC). Resistance was assessed by a population analysis profile (PAP) conducted after 24 h of treatment. Polymyxin B achieved a reduction on the order of -2.05 +/- 0.68 log(10) CFU/ml against these A. baumannii isolates, while all isolates grew to control levels with tigecycline monotherapy. Combination therapy with polymyxin B plus 200 mg tigecycline q12h achieved a greater reduction in bacterial density than did therapy with polymyxin B alone (-3.31 +/- 0.71 versus -2.05 +/- 0.68 log(10) CFU/ml, P < 0.001) but not significantly different than combination therapy with 100 mg tigecycline q12h (-2.45 +/- 1.00 log(10) CFU/ml, P = 0.370). Likewise, combination therapy with polymyxin B plus 200 mg tigecycline q12h significantly reduced the AUBC compared to that with polymyxin B alone (62.8 +/- 8.9 versus 79.4 +/- 10.5 log(10) CFU/ml, P < 0.05). No changes in the PAP from baseline were observed for either antibiotic alone. In this study, combination therapy with simulated exposures of polymyxin B and tigecycline at an aggressive dose of 200 mg q12h produced synergistic or additive effects on humans against these multidrug-resistant A. baumannii strains.
引用
收藏
页码:874 / 879
页数:6
相关论文
共 38 条
[11]   In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii [J].
Housman, Seth T. ;
Hagihara, Mao ;
Nicolau, David P. ;
Kuti, Joseph L. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2013, 68 (10) :2296-2304
[12]   Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model [J].
Koomanachai, Pornpan ;
Kim, Aryun ;
Nicolau, David P. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 63 (05) :982-987
[13]   The impact of multidrug resistance on the outcomes of critically ill patients with Gram-negative bacterial pneumonia [J].
Kwa, Andrea L. H. ;
Low, Jenny G. H. ;
Lee, Erin ;
Kurup, Asok ;
Chee, Huei-Leng ;
Tam, Vincent H. .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2007, 58 (01) :99-104
[14]   Synergistic Activity of Colistin and Rifampin Combination against Multidrug-Resistant Acinetobacter baumannii in an In Vitro Pharmacokinetic/Pharmacodynamic Model [J].
Lee, Hee Ji ;
Bergen, Phillip J. ;
Bulitta, Jurgen B. ;
Tsuji, Brian ;
Forrest, Alan ;
Nation, Roger L. ;
Li, Jian .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (08) :3738-3745
[15]   Quantitation of tigecycline, a novel glycyclcycline, by liquid chromatography [J].
Li, CH ;
Sutherland, CA ;
Nightingale, CH ;
Nicolau, DP .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2004, 811 (02) :225-229
[16]   In-Vitro Activity of Polymyxin B, Rifampicin, Tigecycline Alone and in Combination against Carbapenem-Resistant Acinetobacter baumannii in Singapore [J].
Lim, Tze-Peng ;
Tan, Thean-Yen ;
Lee, Winnie ;
Sasikala, S. ;
Tan, Thuan-Tong ;
Hsu, Li-Yang ;
Kwa, Andrea L. .
PLOS ONE, 2011, 6 (04)
[17]   Emergence and widespread dissemination of OXA-23,-24/40 and-58 carbapenemases among Acinetobacter spp. in Asia-Pacific nations: report from the SENTRY Surveillance Program [J].
Mendes, Rodrigo E. ;
Bell, Jan M. ;
Turnidge, John D. ;
Castanheira, Mariana ;
Jones, Ronald N. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 63 (01) :55-59
[18]   Acinetobacter baumannii 2002-2008: Increase of Carbapenem-Associated Multiclass Resistance in the United States [J].
Mera, Robertino M. ;
Miller, Linda A. ;
Amrine-Madsen, Heather ;
Sahm, Daniel F. .
MICROBIAL DRUG RESISTANCE, 2010, 16 (03) :209-215
[19]   Treatment of Acinetobacter infections [J].
Michalopoulos, Argyris ;
Falagas, Matthew E. .
EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (05) :779-788
[20]   Prevention of Infections Associated With Combat-Related Extremity Injuries [J].
Murray, Clinton K. ;
Obremskey, William T. ;
Hsu, Joseph R. ;
Andersen, Romney C. ;
Calhoun, Jason H. ;
Clasper, Jon C. ;
Whitman, Timothy J. ;
Curry, Thomas K. ;
Fleming, Mark E. ;
Wenke, Joseph C. ;
Ficke, James R. .
JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE, 2011, 71 :S235-S257